SEARCH

MEDIA PACK

NEWS

Current Edition

Adamas

Supernus strikes $400M+ Adamas buyout as its top drug heads toward the patent cliff

As Supernus’ top drug inches toward the patent cliff, the central nervous system-focused drugmaker has struck an M&A deal to quickly expand its portfolio of …

13 October 2021 Regional News Adamas buyout

Continue Reading →

Acceleron

Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180

Merck’s new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks …

13 October 2021 Regional News Acceleron buyout

Continue Reading →

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

SEARCH

MENU

Current Edition

Supernus strikes $400M+ Adamas buyout as its top drug heads toward the patent cliff

Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180

Journal for Clinical Studies